{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T01:22:38Z","timestamp":1784337758189,"version":"3.55.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T00:00:00Z","timestamp":1649980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,24]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Thrombotic microangiopathy is characterised by endothelial cell injury, intravascular platelet-fibrin thrombi, and vascular damage, leading to acute kidney injury, thrombocytopenia, and microangiopathic haemolytic anaemia. Among the autoimmune diseases related to thrombotic microangiopathy, anti-neutrophil cytoplasmic antibody-associated vasculitis-related thrombotic microangiopathy cases have been rarely reported; therefore, the optimal treatment for associated vasculitis-related thrombotic microangiopathy remains unknown. An 84-year-old woman without significant medical history presented with a 1-month history of general fatigue, fever, and deteriorating bilateral leg numbness and was admitted to our hospital. She had elevated myeloperoxidase anti-neutrophil cytoplasmic antibody levels, polyneuropathy, and rapid progressive glomerulonephritis because of pauci-immune crescentic glomerulonephritis, as revealed by a kidney biopsy. Accordingly, we diagnosed her with microscopic polyangiitis. After administering methylprednisolone pulse therapy, rituximab, and intravenous immunoglobulin, the patient\u2019s mental state deteriorated, presenting signs of thrombotic microangiopathy with posterior reversible encephalopathy syndrome. Intermittent haemodialysis and plasma exchange were initiated; however, her condition did not improve, and eculizumab administration was initiated thereafter. The patient\u2019s symptoms showed a remarkable response to eculizumab; thrombotic microangiopathy findings, kidney function, and neurological symptoms improved after only two doses of eculizumab, and she achieved sustained remission. The extremely effective course of eculizumab treatment indicated that overt complement activation affected the development of thrombotic microangiopathy. Anti-neutrophil cytoplasmic antibody-associated vasculitis-related thrombotic microangiopathy may be mediated by complement activation, and prompt induction of eculizumab therapy may be a superior strategy to prevent organ damage. Further studies should elucidate the role of complement activation in associated vasculitis-related thrombotic microangiopathy and the efficacy of eculizumab treatment.<\/jats:p>","DOI":"10.1093\/mrcr\/rxac029","type":"journal-article","created":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T03:11:08Z","timestamp":1649992268000},"page":"254-259","source":"Crossref","is-referenced-by-count":17,"title":["Anti-neutrophil cytoplasmic antibody-associated vasculitis complicated by thrombotic microangiopathy with posterior reversible encephalopathy syndrome successfully treated with eculizumab: A case report"],"prefix":"10.1093","volume":"6","author":[{"given":"Fumiya","family":"Kitamura","sequence":"first","affiliation":[{"name":"Department of Nephrology and Rheumatology, Aichi Medical University , Nagakute, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, Aichi Medical University , Nagakute, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minori","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, Aichi Medical University , Nagakute, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Katsuno","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, Aichi Medical University , Nagakute, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayumi","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, Aichi Medical University , Nagakute, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, Aichi Medical University , Nagakute, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiho","family":"Iwagaitsu","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, Aichi Medical University , Nagakute, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Nobata","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, Aichi Medical University , Nagakute, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kinashi","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, Aichi Medical University , Nagakute, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuji","family":"Ishimoto","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, Aichi Medical University , Nagakute, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Banno","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, Aichi Medical University , Nagakute, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, Aichi Medical University , Nagakute, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,4,15]]},"reference":[{"key":"2022062410420435000_R1","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N Engl J Med"},{"key":"2022062410420435000_R2","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly","year":"2017","journal-title":"Blood"},{"key":"2022062410420435000_R3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ekir.2020.10.009","article-title":"Complement in secondary thrombotic microangiopathy","volume":"6","author":"Palma","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2022062410420435000_R4","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1093\/rheumatology\/kez167","article-title":"Thrombotic microangiopathy associated with anti-neutrophil cytoplasmic antibody-associated vasculitis: a French nationwide retrospective case-control study and literature review","volume":"58","author":"Dellal","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2022062410420435000_R5","article-title":"Management of ANCA associated vasculitis","volume":"368","author":"Wallace","year":"2020","journal-title":"BMJ"},{"key":"2022062410420435000_R6","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.molimm.2015.06.005","article-title":"Complement system activation in ANCA vasculitis: a translational success story?","volume":"68","author":"Kallenberg","year":"2015","journal-title":"Mol Immunol"},{"key":"2022062410420435000_R7","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2013020143","article-title":"C5a receptor (CD88) blockade protects against MPO-ANCA GN","volume":"25","author":"Xiao","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2022062410420435000_R8","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2022062410420435000_R9","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrneph.2017.37","article-title":"Complement in ANCA-associated vasculitis: mechanisms and implications for management","volume":"13","author":"Chen","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"2022062410420435000_R10","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"2022062410420435000_R11","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3109\/s10165-008-0107-3","article-title":"Successful treatment of thrombotic thrombocytopenic purpura with repeated plasma exchange in a patient with microscopic polyangitis","volume":"18","author":"Nagai","year":"2008","journal-title":"Mod Rheumatol"},{"key":"2022062410420435000_R12","first-page":"279","article-title":"Successful treatment for thrombotic thrombocytopenic purpura complicated with myeloperoxidase anti-neutrophil cytoplasmic autoantibody-associated vasculitis","volume":"3","author":"Yamauchi","year":"2010","journal-title":"NDT Plus"},{"key":"2022062410420435000_R13","article-title":"Thrombotic microangiopathy and venous thrombosis in a patient with anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"12","author":"Duong","year":"2020","journal-title":"Cureus"},{"key":"2022062410420435000_R14","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1055\/s-0030-1262886","article-title":"Atypical hemolytic uremic syndrome associated with mutations in complement regulator genes","volume":"36","author":"Le Quintrec","year":"2010","journal-title":"Semin Thromb Hemost"},{"key":"2022062410420435000_R15","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1007\/s00467-010-1555-5","article-title":"Genetics and complement in atypical HUS","volume":"25","author":"Kavanagh","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"2022062410420435000_R16","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1007\/s00467-008-0872-4","article-title":"Complement and the atypical hemolytic uremic syndrome in children","volume":"23","author":"Loirat","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"2022062410420435000_R17","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","article-title":"Dynamics of complement activation in aHUS and how to monitor eculizumab therapy","volume":"124","author":"Noris","year":"2014","journal-title":"Blood"},{"key":"2022062410420435000_R18","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2353\/ajpath.2007.060573","article-title":"Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies","volume":"170","author":"Xiao","year":"2007","journal-title":"Am J Pathol"},{"key":"2022062410420435000_R19","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/ki.2012.313","article-title":"Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"83","author":"Gou","year":"2013","journal-title":"Kidney Int"},{"key":"2022062410420435000_R20","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.2215\/CJN.00120115","article-title":"Association of serum C3 concentration and histologic signs of thrombotic microangiopathy with outcomes among patients with ANCA-associated renal vasculitis","volume":"10","author":"Manenti","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022062410420435000_R21","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.kint.2019.01.023","article-title":"Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors","volume":"95","author":"Le Clech","year":"2019","journal-title":"Kidney Int"},{"key":"2022062410420435000_R22","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022062410420435000_R23","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1182\/blood.2020010234","article-title":"Eculizumab and aHUS: to stop or not","volume":"137","author":"Brodsky","year":"2021","journal-title":"Blood"},{"key":"2022062410420435000_R24","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/jnnp-2017-316225","article-title":"Controversy of posterior reversible encephalopathy syndrome: what have we learnt in the last 20 years?","volume":"89","author":"Gao","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2022062410420435000_R25","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jstrokecerebrovasdis.2011.03.011","article-title":"Blood pressure fluctuations in posterior reversible encephalopathy syndrome","volume":"21","author":"Rabinstein","year":"2012","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"2022062410420435000_R26","article-title":"Posterior reversible leukoencephalopathy syndrome as a presenting manifestation of p-ANCA-associated vasculitis","volume":"2014","author":"Patel","year":"2014","journal-title":"BMJ Case Rep"},{"key":"2022062410420435000_R27","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s00296-011-1982-z","article-title":"Posterior reversible encephalopathy syndrome in ANCA-associated vasculitis","volume":"32","author":"Zhang","year":"2012","journal-title":"Rheumatol Int"},{"key":"2022062410420435000_R28","doi-asserted-by":"crossref","first-page":"427","DOI":"10.4065\/mcp.2009.0590","article-title":"Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings","volume":"85","author":"Fugate","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"2022062410420435000_R29","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s11239-021-02431-5","article-title":"Neurological manifestations of thrombotic microangiopathy syndromes in adult patients","volume":"51","author":"Weil","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"2022062410420435000_R30","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/ndt\/gfm594","article-title":"Posterior reversible encephalopathy induced by intravenous immunoglobulin","volume":"23","author":"Belmouaz","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"2022062410420435000_R31","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003173","article-title":"Calcineurin inhibitors associated posterior reversible encephalopathy syndrome in solid organ transplantation report of 2 cases and literature review","volume":"95","author":"Song","year":"2016","journal-title":"Medicine"},{"key":"2022062410420435000_R32","article-title":"Posterior reversible encephalopathy syndrome associated with tacrolimus in cardiac transplantation","volume":"2021","author":"Rivillas","year":"2021","journal-title":"Case Rep Cardiol"},{"key":"2022062410420435000_R33","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.radcr.2021.03.035","article-title":"Atypical posterior reversible encephalopathy syndrome in a case of thrombotic thrombocytopenic purpura with Sjogren\u2019s syndrome","volume":"16","author":"Hegde","year":"2021","journal-title":"Radiol Case Rep"},{"key":"2022062410420435000_R34","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/1756-185X.13427","article-title":"Rituximab-associated posterior reversible encephalopathy syndrome","volume":"22","author":"Mustafa","year":"2019","journal-title":"Int J Rheum Dis"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxac029\/43404663\/rxac029.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/6\/2\/254\/44245255\/rxac029.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/6\/2\/254\/44245255\/rxac029.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T10:42:52Z","timestamp":1656067372000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/6\/2\/254\/6568599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,15]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,4,15]]},"published-print":{"date-parts":[[2022,6,24]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxac029","relation":{},"ISSN":["2472-5625"],"issn-type":[{"value":"2472-5625","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2022,4,15]]}}}